We’re Investors
Solving the challenges of early-stage investing
Everyone wants to invest in the next big thing before its price skyrockets. Early-stage investing is risky. As an investor you shouldn’t have to rely on gut feel and a powerpoint to understand the potential. Once you’ve invested, you’re an owner so you shouldn’t have to chase the company for regular updates. When you do get an update, you want transparency; information related to the challenges faced by the company, although maybe even expected, such as missed targets, shouldn’t be left or marginalized. The same tools available to invest and easily manage a portfolio of publicly traded companies are not available for private investors. That’s why we built SUMS.
Smart Money
Investors and founders need tools that promote accountability
6x
Early-Stage companies leverage their angel investments to raise $4 billion total – a 6X multiple
Diversify
Angel investors are narrowing the gap, investing in more diverse founders than ever before.
$73 Trillion
More than 10% of North American households are accredited and control more than $73 Trillion in wealth
4 Million+
potential investors but only 10,000 to 15,000 are believed to belong to angel groups in the U.S.
Our Values
Level the Playing Field
We’re committed to providing each with the tools and information required to solve many of the challenges faced in early stage investing. By doing so, we will improve the fluidity of capital to early-stage companies and level the playing field for founders and investors alike.
Create Opportunities
Provide new early-stage investors the opportunities available in impactful companies
Raise the bar
Increase the standards for early stage-investing
Fully Engage
A centralized platform for private investments, SUMS allows investors to easily track the progress of their portfolio with modern analysis, up to date financials and regular company updates.
Meet our Team
Since we began working together our team members have accomplished plenty:
Raised more than $60,000,000 in financing from a global network of investors; >$100,000,000 Exit ; Led successful FDA 510(k) clearance; Sales in 14 different countries; Partnered with some of the world’s most innovative firms.
